BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators
Olivier Castellanet, Fahmida Ahmad, Yaron Vinik, Gordon B. Mills, Bianca Habermann, Jean‐Paul Borg, Sima Lev, Fabienne Lamballe, Flavio Maina
Abstract
Our studies illustrate the possibility to exploit the vulnerability of TNBC cells to CDK1/2/4 inhibition by targeting BCL-XL. Moreover, they underline that specificity matters in targeting cell cycle regulators for combinatorial anticancer therapies.
Topics & Concepts
Triple-negative breast cancerCyclin-dependent kinase 1Cell cycleCell cycle checkpointCancer researchBiologyCell growthCellBreast cancerCancerGeneticsFOXO transcription factor regulationPARP inhibition in cancer therapyAdvanced Breast Cancer Therapies